-
Original Article
-
Korean J Obstet Gynecol. 2003;46(1):22-27. Published online January 1, 2003.
- A Clinical Study of Borderline Malignant Tumors of the Ovary.
-
Jung Heon Lee, Jung Joon Kim, Chul Soo Sin, Jeong Sil Park, Kwang Soo Han, Koock Hwoan Bae
-
Department of Obstetrics and Gynecology, Maryknoll Hospital, Busan, Korea.
- Abstract
- OBJECTIVE
To evaluate the clinical and histopathological features, treatment and prognosis of borderline ovarian tumors (BOT). METHODS: Thirty nine cases of BOT were treated between January 1985 and December 2001 at Maryknoll Hospital. All of BOT were classified in accordance with the WHO criteria for histological typing and clinical staging according to the FIGO system. The clinical records of all patients were reviewed retrospectively. RESULTS: The incidence of BOT was 21.0% (39/186) of epithelial ovarian malignancies and patients with these tumors tended to present at younger age (36.6 years old) than those with invasive carcinoma (53.6 years old). Fourteen patients (35.9%) were nullipara. The most common chief complaint was palpable mass (28.2%). Serous type (17.9%) occurred less frequently than mucinous type (76.9%). The positive ratio of CA 125 was 45%. Stage I was 37 cases (94.8%), stage II, 1 case (2.6%), and stage III, 1 case (2.6%). The mean size of mucinous tumors was larger than that of serous types (18.7 cm vs 10.0 cm). Twenty three (59%) cases were managed by conservative surgery (unilateral salpingo-oophorectomy) and sixteen cases (41%) by extirpative operation. Post-operative adjuvant chemotherapy was given to seven patients (17.9%). Median follow-up period was 30 months. One patient expired in case of mucinous tumor and seven cases lost during follow-up. Overall survival rate was 96.9%. CONCLUSION: Borderline ovarian tumors constitute approximately 21.0% of epithelial ovarian malignancy and occur in younger patients than those with invasive cancer. It is mostly seen serous and mucinous types and most of them are diagnosed at early stage making definite treatment possible.
Keywords :Borderline ovarian tumor (BOT)
